Body Fat Percentage Is a Major Determinant of Total Bilirubin Independently of UGT1A1*28 Polymorphism in Young Obese

Luís Belo1,2,*1, Henrique Nascimento1,2,², Michaela Kohlova3, Elsa Bronze-da-Rocha1,2, João Fernandes1,3, Elídio Costa1,2, Cristina Catarino1,2, Luísa Aires4,5, Helena Ferreira Mansilha6, Petronila Rocha-Pereira7, Alexandre Quintanilha2,8, Carla Rêgo9, Alice Santos-Silva1,2

1 Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal, 2 Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal, 3 Instituto for Biomedical Imaging and Life Science (IBILI), Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal, 4 Centro de Investigação em Actividade Física, Saúde e Lazer (CIAFEL), Faculdade de Desporto, Universidade do Porto, Porto, Portugal, 5 Instituto Universitário da Maia (ISMAI), Maia, Portugal, 6 Departamento da Infância e Adolescência/Serviço de Pediatria do Centro Hospitalar do Porto, Porto, Portugal, 7 Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal, 8 Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, Porto, Portugal, 9 Centro da Criança e do Adolescente. Hospital CUF Porto, Porto, Center for Health Technology and Services Research (CINTESIS), Faculdade de Medicina, Universidade do Porto, Porto, Portugal

Abstract

Objectives: Bilirubin has potential antioxidant and anti-inflammatory properties. The UGT1A1*28 polymorphism (TA repeats in the promoter region) is a major determinant of bilirubin levels and recent evidence suggests that raised adiposity may also be a contributing factor. We aimed to study the interaction between UGT1A1 polymorphism, hematological and anthropometric variables with total bilirubin levels in young individuals.

Methods: 350 obese (mean age of 11.6 years; 52% females) and 79 controls (mean age of 10.5 years; 59% females) were included. Total bilirubin and C-reactive protein (CRP) plasma levels, hemogram, anthropometric data and UGT1A1 polymorphism were determined. In a subgroup of 74 obese and 40 controls body composition was analyzed by dual-energy X-ray absorptiometry.

Results: The UGT1A1 genotype frequencies were 49.9%, 42.7% and 7.5% for 6/6, 6/7 and 7/7 genotypes, respectively. Patients with 7/7 genotype presented the highest total bilirubin levels, followed by 6/7 and 6/6 genotypes. Compared to controls, obese patients presented higher erythrocyte count, hematocrit, hemoglobin and CRP levels, but no differences in anthropometric variables with total bilirubin levels in young individuals. This inverse association was observed either in 6/7 or 6/6 genotype obese patients. UGT1A1 polymorphism and body fat percentage were the main factors affecting bilirubin levels within obese patients (linear regression analysis).

Conclusion: In obese children and adolescents, body fat composition and UGT1A1 polymorphism are independent determinants of total bilirubin levels. Obese individuals with 6/6 UGT1A1 genotype and higher body fat mass may benefit from a closer clinical follow-up.

Introduction

Bilirubin is the ultimate product of the haem group catabolism and serves as a diagnostic marker of liver and blood disorders [1]. Bilirubin is a water-insoluble compound that circulates bounded to albumin and requires glucuronidation by a microsomal enzyme, the uridine diphosphate glucuronosyltransferase (UGT) 1A1, to be excreted. The UGT1A1 gene locus has been mapped to chromosome 2q37 [2] and one of the most common genetic variants that affects the glucuronidation of bilirubin is a TA duplication polymorphism in the TATA box region of the gene promoter. Homozygous individuals carrying the A(TA)7TAA allele have higher levels of unconjugated bilirubin (UCB), caused by a reduction of 30% in the UGT1A1 transcription [3]. The estimated frequency of this allele is 0.35 in Caucasians, leading to a
homozygous genotype in about 10% of the population, but the frequency is highly variable in different ethnicities [4,5]. Homozygosis for the TA duplication was considered as the main cause of Gilbert syndrome in Caucasian population [3,4], and justify some of the inter-individual variations in bilirubin levels [6].

Under certain conditions bilirubin can be toxic [7]. High plasma concentrations are associated with deleterious effects in new-borns, increasing the risk of neurological dysfunction [7,8], as a result of its toxic effect on neuronal tissue. However, recent investigation has recognized that UCB exerts anti-oxidant and anti-inflammatory activities, and that mild hyperbilirubinemia might have positive health effects. UCB inhibits lipid peroxidation [9] and suppresses inflammation in activated neonatal neutrophils[10], and population studies documented that individuals with higher circulating UCB have a reduced incidence of cardiovascular problems [11–13] and of carcinoma in general [14]. Furthermore, subjects with Gilbert syndrome seem to present low levels of oxidative stress associated with hyperbilirubinemia [15].

Obesity, a low-grade inflammatory disease [16], is increasing all over the world and is a significant risk factor for cardiovascular diseases (CVD). This is of particular concern in our country, considering the very high prevalence of overweight/obesity (31.5%) in Portuguese children when compared to other European countries [17]. In obesity, cardiovascular morbidity and mortality are associated with classic risk factors, namely dyslipidaemia, hypertension and impaired glucose metabolism. These risk factors, known as predictive of CVD, are characteristic of the metabolic syndrome (MS) [18]. Moreover, serum bilirubin levels are inversely associated with the MS and systemic inflammation in adults [19–21], as well as in children and adolescents [22]. In particular, abdominal obesity per se seems to be associated with low serum bilirubin levels [21–23]. Furthermore, a recent study hypothesized that circulating bilirubin levels might be already altered in overweight asymptomatic middle-aged individuals before full development of the MS [24].

The aim of our work was to evaluate how total bilirubin (TB) levels are influenced by UGT1A1*28 polymorphism, haematological, biochemical and anthropometric variables in Portuguese obese children and adolescents.

Materials and Methods

2.1. Subjects

Obese children and adolescents, aged 4–18 years, were identified from medical records, at the outpatient clinics of pediatric obesity in two hospitals in Porto - Portugal. A group of children from 5 primary and 2 middle and high public schools from Oporto suburban setting, were also recruited to this study, providing a control group and enlarging the obese group.

The study protocol was approved by the Committee on Ethics of Oporto Hospital Centre, the Committee on Ethics of Hospital São João, the Review Committee of the Scientific Board of the Faculty of Sport of the University of Porto as well as by the Foundation of Science and Technology.

As referred, the main objective of this study was to investigate total bilirubin levels in obese and non-obese subjects; thus, the sample size was based on this main variable. Considering the difficulty of getting blood samples from non-obese, healthy subjects, the sample size relation between obese and controls was set up as 4:1. Assuming that a clinical relevant difference between experimental and control was 1 unit of bilirubin, and a common standard deviation of 3 units of bilirubin, for a relation of 4:1, the sample size calculations, for a power of 80% and a significant level of 5%, define, respectively, 335 obese to 89 controls. In accordance, we tried to achieve these numbers as close as possible; a total of 350 obese children and adolescents and 79 controls participated in the study after informed and written consent of their parents. Smokers, subjects with diabetes mellitus, endocrine disorders, hereditary diseases, inflammatory or infectious diseases or under any therapy that could interfere with our results were excluded from the study.

2.2. Procedures and Assays

2.2.1. Anthropometric characterization and clinical evaluation. All participants were subjected to clinical examination. Height and weight were measured. Obesity was defined as body mass index (BMI) z-score greater than +1.65 for age and gender, according to 2000 Centre for Disease Control and Prevention (CDC) growth charts. Body composition was evaluated by dual-energy X-ray absorptiometry (DEXA) in a subgroup of participants (74 obese and 40 controls).

2.2.2. Blood samples. Blood was collected by venipuncture in EDTA containing tubes, after overnight fasting (10–12 h) and processed within 2 h of collection. Aliquots of buffy-coat and plasma were made, and immediately stored at −80°C until assayed.

2.2.3. Haematological data. Red blood cell (RBC) count, haematocrit (Ht), haemoglobin (Hb) concentration and haematocrit values [mean cell volume (MCV), mean cell Hb (MCH) and mean cell Hb concentration (MCHC)] were measured by using an automatic blood cell counter (ABX Micros 60-OT).

2.2.4. DNA analysis. Genomic DNA was extracted from buffy-coat by proteinase K/salt precipitation method [25,26]. Genotyping TA duplication in the TATA box of the UGT1A1 promoter was performed by polymerase chain reaction (PCR) (forward: 5'-TAACTTGCTATCGATTGGTTTTTG-3'; reverse: 5'-ACAGCCATGGGCCCTTGT-3'). PCR was followed by electrophoresis in 15% polyacrylamide gel in a Tris/ Borate/EDTA buffer. The gel was stained with silver nitrate, photographed and samples were classified.

2.2.5. Plasma analysis. The plasma levels of C-reactive protein (CRP) were determined by immunoturbidimetry [CRP (latex) High-Sensitivity, Roche Diagnostics] and quantification of TB was performed by a colorimetric test (diazotized sulfanilic acid reaction, Roche Diagnostics).

The determination of circulating levels of glucose and insulin was performed by using routine automated technology (ABX Diagnostics). Homeostasis model assessment of insulin resistance (HOMA) was calculated [27].

2.3. Statistical Analysis

The distributions of continuous variables were analysed using Kolmogorov-Smirnov tests. Normally distributed variables are presented as mean ± SD and those non-normally distributed are presented as median (interquartile range). Comparisons between two groups were performed using Student’s unpaired t-test or Mann-Whitney U test. Adjustment for confounding factors was performed using ANCOVA. The association between categorical variables was analysed using chi-squared (χ²) test and Fisher’s exact test.

The strength of the association between the variables was estimated by Pearson correlation coefficient, after log transformation of the variables (whenever necessary). To evaluate the contribution of the different variables to TB levels, multiple regression analysis was performed, using stepwise selection, with an entry criteria of p<0.05.
Table 1. Anthropometric data, UGT1A1*28 polymorphism, haematological and biochemical parameters of the participants in the study.

|                      | Controls (n=79) | Obese patients (n=350) | p   |          |          |      |
|----------------------|----------------|------------------------|-----|----------|----------|------|
|                      | Females        | Males                  |     |          |          |      |
| Number of participants| 47             | 32                     |     |          |          |      |
| Age (years)          | 10.5±4.0       | 10.7±3.6               | 0.83|          |          |      |
| Height (cm)          | 139.7±17.9     | 143.8±17.6             | 0.317|          |          |      |
| Weight (kg)          | 37.0±14.6      | 39.7±15.8              | 0.440|          |          |      |
| BMI (kg/m²)          | 18.1±2.9       | 18.3±2.9               | 0.691|          |          |      |
| BMI z-score          | 0.17±0.65      | 0.24±0.77              | 0.636|          |          |      |
| Body fat (%)         | 30.8±4.1       | 25.4±5.2               | 0.001|          |          |      |
| Trunk fat (%)        | 25.6±4.8       | 21.9±6.0               | 0.045|          |          |      |
| UGT1A1 genotype      |                |                        |     |          |          |      |
| 6/6, n (%)           | 21 (44.7%)     | 92 (50.6%)             | 0.298|          |          |      |
| 6/7, n (%)           | 21 (44.7%)     | 79 (43.4%)             |      |          |          |      |
| 7/7, n (%)           | 5 (10.6%)      | 11 (60.0%)             |      |          |          |      |
| RBC (×10¹²/L)        | 462±0.29       | 478±0.32               | 0.031|          |          |      |
| Hb (g/dL)            | 13.1±0.9       | 13.6±0.8               | 0.029|          |          |      |
| Ht (L/L)             | 0.39±0.03      | 0.40±0.04              | 0.263|          |          |      |
| MCV (fL)             | 84.9±6.4       | 84.2±5.1               | 0.486|          |          |      |
| MCH (pg)             | 28.4±1.7       | 28.5±1.7               | 0.684|          |          |      |
| MCHC (g/dL)          | 33.4±1.2       | 33.7±1.1               | 0.025|          |          |      |
| Total bilirubin (µmol/l) | 8.89 (5.47–13.34) | 8.89 (6.64–11.63) | 0.463|          |          |      |
| Acute phase protein  |                |                        |     |          |          |      |
| CRP (mg/L)           | 0.26 (0.20–0.73)| 0.36 (0.26–0.83)      | 0.121|          |          |      |
| Glucose metabolism   |                |                        |     |          |          |      |
| Glucose (mg/dl)      | 85.3±9.3       | 87.0±6.5               | 0.365|          |          |      |
| Insulin (µU/ml)      | 68 (50–9.9)    | 16.6 (11.7–23.2)       | 0.051|          |          |      |
| HOMA ß                | 1.41 (1.06–2.05)| 1.14 (0.82–1.83)      | 0.130|          |          |      |

Values are given as mean ± SD or median (interquartile range), unless otherwise indicated.

BMI, body mass index; RBC, red blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean cell volume; MCH, mean cell haemoglobin; MCHC, mean cell haemoglobin concentration; CRP, C-reactive protein; HOMA ß, homeostasis model assessment insulin resistance.

* p = 25;
* p = 15;
* p = 15;
* p = 34;
* p = 40.
* Controls versus obese patients (females).
* Controls versus obese patients (males).

doi:10.1371/journal.pone.0098467.t001
This difference was not statistically significant (more prevalent in male controls than in male obese patients, but significantly) higher in female obese patients. The “7” allele was (Table 1), with exception for MCHC values that were slightly (but similar when groups were analysed separately according to gender UGT1A1 genotype distribution (respectively.

Comparing males and females within the control group, body fat and trunk fat percentages were significantly lower for boys, whereas RBC count, Hb levels and MCHC values were significantly higher. Within obese patients, RBC count, Hb levels and Ht values were significantly higher for boys, whereas insulin levels and HOMAIR values were lower. No statistical significant differences were found in the distribution of subjects with respect to UGT1A1 genotypes or in TB levels between boys and girls, within both groups.

Compared to controls, and as expected considering the inclusion criteria, obese patients presented significantly higher height, weight, BMI, BMI z-score, body fat and trunk fat percentages ($p<0.001$ for all). Obese patients also presented significantly higher erythrocyte count, Ht and HOMAIR values and Hb, insulin and CRP levels ($p<0.001$ for all), but no significant differences in TB levels ($p=0.222$), MCV ($p=0.432$), MCH ($p=0.474$), MCHC ($p=0.603$), glucose ($p=0.389$) or in UGT1A1 genotype distribution ($p=0.244$). These results were similar when groups were analysed separately according to gender (Table 1), with exception for MCHC values that were slightly (but significantly) higher in female obese patients. The “7” allele was more prevalent in male controls than in male obese patients, but this difference was not statistically significant ($p=0.085$).

The UGT1A1 genotype frequencies in all studied individuals were 49.9%, 42.7% and 7.5% for 6/6, 6/7 and 7/7 genotypes, respectively. UGT1A1*28 polymorphism was associated with different TB levels (Figure 1A); patients with 7/7 genotype presented the highest TB levels, followed by 6/7 and 6/6 genotypes ($p<0.01$ between all groups). No significant differences in TB levels were observed between obese and control individuals, for the different UGT1A1 genotypes (Figure 1B).

Within the control group ($n=79$), TB levels correlated positively and significantly with age ($r=0.304$, $p=0.007$), height ($r=0.360$, $p=0.001$), weight ($r=0.390$, $p<0.001$), BMI ($r=0.370$, $p=0.001$), Ht ($r=0.247$, $p=0.028$), MCV ($r=0.292$, $p=0.009$), and correlated negatively and significantly with MCHC ($r=-0.258$, $p=0.022$). Within the obese group ($n=350$), TB levels correlated positively and significantly with age ($r=0.284$, $p<0.001$), height ($r=0.285$, $p<0.001$), weight ($r=0.219$, $p<0.001$), BMI ($r=0.123$, $p=0.021$), Hb ($r=0.305$, $p<0.001$), Ht ($r=0.352$, $p<0.001$), MCV ($r=0.394$, $p<0.001$), MCH ($r=0.301$, $p<0.001$) and correlated negatively and significantly with BMI z-score ($r=-0.131$, $p=0.014$), MCHC ($r=-0.149$, $p=0.006$) and CRP ($r=-0.178$, $p=0.001$).

The characteristics of obese patients whose body composition was evaluated by DEXA ($n=74$) are presented in Table 2. These obese patients were divided in two groups according on having a body fat lower or higher/equal than 42.5% (cut-off that corresponds to the median value for the obese group). The two groups of obese patients were matched for gender and UGT1A1 genotype distribution, but not for age. Patients presenting higher body fat had lower bilirubin and higher CRP levels (Table 2). These differences were similar to both sexes (Figure 2) and remained statistically significant after adjustment for age. No significant differences in HOMAIR values were found between the two groups.

Associations between body and trunk fat were only accessed in participants that evaluated their body composition by DEXA (74 obese and 40 controls). Body fat and trunk fat percentages were negatively and significantly related with TB levels in obese patients ($r=-0.287$, $p=0.013$ and $r=-0.245$, $p=0.038$) but not within controls ($r=0.012$, $p=0.941$ and $r=0.014$, $p=0.002$).

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS), version 20.0 (IBM, Armonk, NY, USA). Statistical significance was accepted at $p$ less than 0.05.

**Results**

The anthropometric data, UGT1A1 genotypes and haematological parameters of the obese children and adolescents ($n=550$) and controls ($n=79$), according to gender, are presented in Table 1.

Comparing males and females within the control group, body fat and trunk fat percentages were significantly lower for boys, whereas RBC count, Hb levels and MCHC values were significantly higher. Within obese patients, RBC count, Hb levels and Ht values were significantly higher for boys, whereas insulin levels and HOMAIR values were lower. No statistical significant differences were found in the distribution of subjects with respect to UGT1A1 genotypes or in TB levels between boys and girls, within both groups.

**Figure 1. Total bilirubin levels in all participants according to the number of TA repeats in the promoter region of UGT1A1 gene (A) and also according to group (B), control and obese.** The boxes represent the interquartile range (IQR), with the upper and lower edges of the boxes representing the 75th and 25th percentiles, respectively. The central horizontal lines within the boxes represent median levels for each group. The vertical whiskers above and below the boxes represent the range of outlying data points up to 1.5 times the IQR.

doi:10.1371/journal.pone.0098467.g001

**Table 1.** UGT1A1 genotype frequencies in all studied individuals

| Genotype | UGT1A1*28 | n | % |
|----------|-----------|---|---|
| 6/6      | 337        | 79.1 | 27.2 |
| 6/7      | 163        | 36.7 | 37.0 |
| 7/7      | 60         | 12.9 | 7.6  |

The values of statistical significance are presented in parentheses.
By linear regression analysis, the UGT1A1*28 polymorphism and body weight were the only factors associated to bilirubin levels within controls (Ln TB = 1.143 + 0.462 UGT1A1*28 polymorphism + 0.014 weight; standardised Beta: 0.598 and 0.490; p = 0.001 and p = 0.001, respectively). Within obese patients, the UGT1A1 polymorphism and body fat percentage were the main determinants of bilirubin levels (Ln TB = 2.761 + 0.251 UGT1A1*28 polymorphism + 0.020 body fat; standardised Beta: 0.348, 0.291; p = 0.002 and p = 0.009, respectively). For a better visualization of the results (graphically), obese participants were divided on the basis of their UGT1A1 genotype and on having a body fat lower or higher/equal than 42.5% (cut-off that corresponds to the median value for the obese group; Figure 3).

Discussion

As far as we know, this is the first report assessing the concomitant influence of UGT1A1*28 polymorphism and adiposity markers on bilirubin levels in obese children and adolescents. We demonstrated that body fat percentage is a major determinant of TB levels independently of UGT1A1*28 polymorphism in obese children and adolescents.

It is known that UGT1A1 polymorphisms are associated with bilirubin levels and our data are in agreement with previous reports in young patients and adults [15,28–30]. Patients and controls with 7/7 genotype presented the highest TB levels, followed by 6/7 and 6/6 genotypes (Figure 1A and 1B).

The frequency of 7/7 homozygotes (7.5% in the whole population) was lower than that observed in other works, namely in healthy Greek [29] and Slovenian [30] populations, with frequencies of 14.8% and 13.6%, respectively. However, the distribution of subjects with respect to UGT1A1 genotypes was similar to that found in previous studies involving Portuguese children with Hereditary Spherocytosis, with a 7/7 frequency of 8.8% [28], as well as Portuguese healthy subjects, with frequencies observed in two studies of 6.3 and 9.9% [28,31]. Thus, it seems reasonable to assume that the frequency of 7/7 homozygotes in the Portuguese population may be lower than that observed in other Caucasian populations.

Other potential variables could influence TB levels. Within both controls and obese patients TB levels were positively and

| Table 2. Anthropometric data, UGT1A1*28 polymorphism, haematological and biochemical parameters of obese patients according to body fat percentage (n = 74) lower or higher/equal than 42.5% (median value for the obese group). |
|---------------------------------|-----------------|-------------------|-----|
| Obese patients (n = 74)         | Body fat ≤42.5% | Body fat >42.5%   | p   |
|---------------------------------|-----------------|-------------------|-----|
| Number of participants          | 37              | 37                |     |
| Female, n (%)                   | 13 (35.1%)      | 21 (56.8%)        | 0.102|
| Age (years)                     | 11.0±3.0        | 9.5±2.5           | 0.022|
| Height (cm)                     | 149.2±14.3      | 144.0±14.2        | 0.126|
| Weight (kg)                     | 59.8±18.9       | 61.4±23.9         | 0.749|
| BMI (kg/m²)                     | 26.0±4.0        | 28.4±5.5          | 0.041|
| BMI z-score                     | 1.98±0.24       | 2.31±0.26         | <0.001|
| Body fat (%)                    | 36.8±4.3        | 46.1±2.6          | <0.001|
| Trunk fat (%)                   | 34.5±5.5        | 45.3±3.4          | <0.001|
| UGT1A1 genotype                 |                 |                   |     |
| 6/6, n (%)                      | 21 (56.8%)      | 19 (51.4%)        | 0.359|
| 6/7, n (%)                      | 14 (37.8%)      | 18 (48.6%)        |     |
| 7/7, n (%)                      | 2 (5.4%)        | 0 (0%)            |     |
| RBC (×10³/L)                    | 4.83±0.38       | 4.91±0.34         | 0.389|
| Hb (g/dL)                       | 13.9±1.0        | 13.6±0.8          | 0.268|
| Ht (L/L)                        | 0.41±0.03       | 0.41±0.02         | 0.798|
| MCV (fL)                        | 85.4±4.9        | 83.8±4.6          | 0.156|
| MCH (pg)                        | 28.7±1.7        | 27.8±1.5          | 0.017|
| MCHC (g/dL)                     | 33.6±0.8        | 33.2±0.9          | 0.020|
| Total bilirubin (µmol/l)        | 11.29 (8.72–14.36) | 8.89 (7.69–11.63) | 0.013|
| Acute phase protein             |                 |                   |     |
| CRP (mg/L)                      | 1.31 (0.84–2.30) | 2.00 (1.43–3.54) | 0.017|
| Glucose metabolism              |                 |                   |     |
| Glucose (mg/dl)                 | 83.5±7.6        | 81.0±8.6          | 0.191|
| Insulin (µU/ml)                 | 11.6 (8.9–14.6) | 15.3 (7.5–22.9)  | 0.272|
| HOMA, Homeostasis model assessment insulin resistance | 2.25 (1.91–3.01) | 3.15 (1.57–4.56) | 0.361|

Values are given as mean ± SD or median (interquartile range), unless otherwise indicated.

BMI, body mass index; RBC, red blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean cell volume; MCH, mean cell haemoglobin concentration; CRP, C-reactive protein; HOMA, homeostasis model assessment insulin resistance.

doi:10.1371/journal.pone.0098467.t002
significantly correlated with age, height, weight, BMI, and Ht. However, BMI z-score, body fat and trunk fat percentages were negatively and significantly related with TB levels in obese patients, but not within controls. In multiple regression analysis, the \textit{UGT1A1*28} polymorphism and body weight were the only factors associated to bilirubin levels within controls, whereas the \textit{UGT1A1*28} polymorphism and body fat percentage were the main determinant factors of bilirubin levels within obese patients.

In the present study, the evaluation of body composition by DEXA was performed in a subgroup of participants. Despite the lower number of participants in this sub-analysis, the negative relation between bilirubin and body fat percentage was highly statistically significant and independent of the effect of \textit{UGT1A1*28} polymorphism. Furthermore, this negative relation is in agreement with a previous study involving 41 lean and obese adult men and women [23].

Bilirubin derives mainly from the haem present in Hb, released during breakdown of senescent erythrocytes [1]. Thus, in healthy conditions, it would be assumed that increases in Hb levels are generally associated with increases in TB. This explains our positive association between the age of the participants and TB, as in young individuals there is a physiological increase in Hb levels with age. It is well known that Hb and Ht increase substantially during childhood, whereas RBC count remains almost constant [32]. Differences according to gender become prominent in the second decade of life; with menstruation, these three variables tend to be lower in females. The inclusion in our study of subjects with a range of age between 4 and 18 years old justifies the higher values of RBC and Hb observed in males within both controls and obese patients (Table 1). The higher weight and BMI in obese patients trigger the stimulation of erythropoiesis in order to supply adequate oxygenation to increased body tissues. The lower values of MCHC in those with higher body fat (Table 2) show a reduced hemoglobinization of the erythrocytes, suggesting an underlying disturbance in iron metabolism that might be due to a higher degree of inflammation presented by these individuals (significantly higher CRP), which may interfere with iron absorption and iron mobilization for erythropoiesis [36].

Despite higher RBC count and Hb levels in obese patients, TB levels were similar between groups. A speculative explanation to this observation is bilirubin consumption occurring in obesity, a hypothesis shared by others [24]; obesity is associated with increased inflammation [16,37,38] and oxidative stress [39,40], and bilirubin, presenting antioxidant and anti-inflammatory
properties [9,10], may be somewhat consumed. In fact, oxidative stress increases with increasing BMI and age [34]. In line with this, we found that bilirubin levels are negatively correlated with body and trunk fat percentages and CRP levels within obese patients. Moreover, when obese patients were divided in two groups according to the median value of body fat presented by this group (42.5%), patients presenting higher body fat presented lower bilirubin and higher CRP levels (Table 2). The negative relation that we found between bilirubin and CRP levels is in line with the bilirubin's anti-inflammatory activity, as previously reported [41–44].

In obese patients, insulin resistance may also underlie the association between lower bilirubin levels and higher body fat percentages. Indeed, it seems that the activity of heme oxygenase-1, the rate-limiting enzyme of bilirubin production, is impaired in insulin resistant states [45,46]. Also, the up-regulation of heme oxygenase-1 in adipocyte by insulin was recently demonstrated [47]. In this work obese patients presented higher HOMA\textsubscript{IR} values compared to controls (Table 1). Obese patients with body fat percentages higher than 42.5% also presented higher HOMA\textsubscript{IR} values, although without statistical significance. However, no significant correlation was obtained between HOMA\textsubscript{IR} and bilirubin. Thus, association between insulin resistance and bilirubin might not be so clear in paediatric populations.

A previous work from our group demonstrated that BMI z-score is significantly and independently related to the lipid profile in obese children and adolescent [48]. However, in the present study BMI z-score was poorly related with TB levels in obese patients and it was not an independent predictor of bilirubin plasma concentration. This suggests that body fat percentage is a better indirect marker of oxidative stress, rather than BMI z-score. Actually BMI z-score is calculated using the BMI of patients, adjusted to age and gender, but it may not necessarily express the degree of obesity.

Figure 3. Effect of body fat percentage on total bilirubin levels according to \textit{UGT1A1*28} polymorphism on obese patients. For a better visualization of the results we used for body fat percentage a cut-off of 42.5% (cut-off that corresponds to the median value for the obese group). Results are presented as mean ± standard error of mean. The influence of body fat percentage, adjusted for \textit{UGT1A1} polymorphism, on total bilirubin levels, was highly significant (p = 0.009), by multiple regression analysis. doi:10.1371/journal.pone.0098467.g003
Individuals with a higher physical fitness index (which serves as an aerobic assessment) seem to present with higher bilirubin levels [24] and a study performed in overweight and obese adult patients demonstrated an increase in bilirubin levels due to short-term weight loss [35]. It seems that high doses of exercise training are necessary to significantly increase bilirubin levels in overweight and obese women [49]. The fact that bilirubin levels increase as a function of weight loss may be of particular importance in obese individuals with UGT1A1 genotypes associated to lower bilirubin levels, as we here demonstrated effects on TB by body fat composition in addition to the UGT1A1*28 polymorphism. It is important to keep in mind that atherosclerosis is a multifactorial disease that initiates early in life, involving the interplay of genetic and environmental factors. The lifestyle improvement is conditioned by environmental factors (such as nutritional behaviour and practice of physical activity) and may be particularly worthy in obese individuals with a less favourable genetic background.

Despite the new data reported here, this work presented some limitations. Obesity was defined according to CDC although a novel criteria is now recommended for the Portuguese population, causing us to have probably underestimated the degree of obesity. Nevertheless, at the beginning of this study the criteria recommend by the Portuguese Ministry of Health was that of CDC. Also, the number of controls was small to evaluate UGT1A1 by the Portuguese Ministry of Health was that of CDC. Nevertheless, at the beginning of this study the criteria recommend by the Portuguese Ministry of Health was that of CDC. Also, the number of controls was small to evaluate UGT1A1 genotype distribution in cases and controls; actually, besides ethics requirements, parental approval in healthy children and adolescents is difficult to obtain. The evaluation of body composition by DEXA was also performed only in a subgroup of participants due to logistical constraints and equipment availability. Furthermore, we did not evaluate the association between bilirubin and the MS as a large proportion of our obese patients were under the age of 10, not allowing their classification according to the International Diabetes Federation (IDF) definition.

In conclusion, body fat percentage is a major determinant of TB levels independently of UGT1A1*28 polymorphism in obese children and adolescents. This may have a particular relevance, as obese individuals, particularly those with 6/6 UGT1A1 genotype and higher body fat mass, may benefit from a closer clinical follow-up, considering their increased risk for other comorbidities. Moreover, lifestyle modifications at low ages, when good habits can be created, should be highly encouraged in such obese children and adolescents.

**Acknowledgments**

The authors wish to thank: 1) the technician team from Porto Hospital Centre and Hospital São João for their expert assistance on blood collection, 2) Professors Denis Mendonça and Pedro Oliveira for providing statistical counselling, and 3) all the participants who were involved in this project and their parents.

**Author Contributions**

Conceived and designed the experiments: LB HN HFMP RP AQ CR ASS. Performed the experiments: LB HN MK EBR JF CC LA PRP. Analyzed the data: LB HN HFMQ CR ASS. Contributed reagents/materials/analysis tools: LB HN MK EBR JF CC LA PRP. Wrote the paper: LB HN CR ASS.

**References**

1. Fevery J (2008) Bilirubin in clinical practice: a review. Liver Int 28: 592–605.
2. Gong QH, Cho JW, Huang T, Potter C, Gholami N, et al. (2001) Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenet Genomics 11: 357–368.
3. Bosna PJ, Chowdhury JR, Bakker C, Gandia S, de Boer A, et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 333: 1171–1175.
4. Beutler E, Gelbart T, Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95: 8170–8174.
5. Caninna N, Kuruse K, Jinno H, Tanaka-Kagawa S, Saito Y, et al. (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 696C>T (P229L) found in an African-American. Drug Metab Dispos 33: 458–463.
6. Clementi M, Di Gianantonio E, Fabris L, Forabosco P, Strazzabosco M, et al. (2007) Inheritance of hyperbilirubinemia: evidence for a major autosomal recessive gene. Dig Liver Dis 39: 351–355.
7. Tiribelli C, Ostrow JD (2005) The molecular basis of bilirubin encephalopathy. J Pediatr 146: 602–608.
8. Liu C, de Groot PG, van der Meer FJ, Backhuijsen A, Hendriksen IR, et al. (2003) Association of the chromosomal location of the bilirubin glucuronosyltransferase gene (UGT1A1) with serum bilirubin levels in healthy adults. Genet Epidemiol 24: 260–268.
9. Ulrich CM, Landsman PB, Grundy SM (2008) The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Metab 10: 246–250.
10. Huang HJ, Kims SH (2010) Inverse relationship between fasting direct bilirubin and diabetic metabolic syndrome in Korean adults. Clin Chim Acta 411: 1496–1501.
11. Lin JP, O’Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, et al. (2013) Effects of bilirubin on neutrophil responses in newborn infants. Neonatology 103: 105–111.
12. Lin JP, O’Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, et al. (2006) Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114: 1476–1481.
13. Novotny L, Vink L (2003) Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 228: 568–571.
14. Horsfall LJ, Nazareth I, Petersen I (2012) Cardiovascular events as a function of weight loss in a large, statin-treated cohort. Circulation 126: 2556–2564.
15. Temme EH, Zhang J, Schouten EG, Kesteloot H (2001) Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12: 807–814.
16. Nascimento H, Costa E, Pereira P, Rego C, Mansilha HH, et al. (2012) Cardiovascular risk factors in Portuguese obese children and adolescents: impact of small reductions in body mass index imposed by lifestyle modifications. Open Biomed J 6: 43–50.
17. Padez C, Fernandes T, Mourao I, Moreira P, Rosado V (2004) Prevalence of overweight and obesity in 7–9-year-old Portuguese children: trends in body mass index from 1970–2002. Am J Hum Biol 16: 670–674.
18. Alexander CM, Linsdam PB, Grundy SM (2008) The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Metab 10: 246–250.
19. Hwang HJ, Kims SH (2010) Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin Chim Acta 411: 1496–1501.
20. Li Y, Li J, Jin H, Qi Y, Lin X, et al. (2011) Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes 3: 217–224.
21. Lin LY, Kuo HK, Huang HJ, Lai LP, Chiang FT, et al. (2009) Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 203: 565–568.
22. Devries MC, Sampjo IA, Hanadeh MJ, Tarnopolsky MA (2008) Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and women. Obesity (Silver Spring) 16: 2281–2288.
23. Jesko-Prajzner Z, Petelin A, Jurdana M, Ziberna L (2013) Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults: an early indicator of metabolic syndrome? Metabolism 62: 976–985.
24. Ollero O, Zetterquist H (1992) HLA-DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39: 225–235.
25. Gaffney D, Campbell RA (1994) A PCR-based method to determine the Kallol allele of the cholinesterase gene: the Elk alleles frequency and its significance in the normal population. J Med Genet 31: 240–250.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.

PLOS ONE | www.plosone.org
8 June 2014 | Volume 9 | Issue 6 | e98467
28. Rocha S, Costa E, Ferreira F, Cleto E, Barbot J, et al. (2010) Hereditary spherocytosis and the (TA)nTAA polymorphism of UGT1A1 gene promoter region—a comparison of the bilirubin plasmatic levels in the different clinical forms. Blood Cells Mol Dis 44: 117–119.

29. Karatzas A, Giannatou E, Tzortzis V, Gravas S, Aravanitos E, et al. (2010) Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men. Cancer Epidemiol 34: 345–349.

30. Otseneck B, Furlan D, Mavec T, Lukac-Bajalo J (2007) UGT1A1(TA)n promoter polymorphism—a new case of a (TA)8 allele in Caucasians. Blood Cells Mol Dis 38: 78–82.

31. Rodrigues C, Vieira E, Santos R, de Carvalho J, Santos-Silva A, et al. (2012) Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients and in healthy subjects. Blood Cells Mol Dis 48: 166–172.

32. Yip R, Johnson C, Dallman PR (1984) Age-related changes in laboratory values used in the diagnosis of anemia and iron deficiency. Am J Clin Nutr 39: 427–436.

33. Chauhan A, Grisson M (2013) Disorders of childhood growth and development: precocious puberty. FP Essent 410: 25–31.

34. Wonisch W, Falk A, Sundl I, Winklhofer-Roob BM, Lindschinger M (2012) Oxidative stress increases continuously with BMI and age with unfavourable profiles in males. Aging Male 15: 159–165.

35. Andersson C, Weeke P, Fosbol EL, Brendorp B, Koher L, et al. (2009) Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism 58: 1109–1115.

36. Coimbra S, Catarino C, Santos-Silva A (2013) The role of adipocytes in the modulation of iron metabolism in obesity. Obes Rev 14: 771–779.

37. Taube A, Schlich R, Sell H, Eckardt K, Eckel J (2012) Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 302: H2148–2165.

38. Greco EA, Francomano D, Fornari R, Marasco C, Lubrano C, et al. (2013) Negative association between trunk fat, insulin resistance and skeleton in obese women. World J Diabetes 4: 31–39.

39. Bonilla-Pons I, Ryan L, Martinez JA (2012) Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem 68: 701–711.